Introduction
============

Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer worldwide and the most common neoplasm in the upper aerodigestive tract. In Brazil, nearly 14,120 new cases of oral cancer are expected in 2010, comprising 3,790 in women and 10,330 in men \[[@R1]\]. Despite some advances in conventional therapies, including surgery, radiation and chemotherapy, the overall survival (OS) rate for HNSCC has not significantly improved in the last three decades \[[@R2]\].

The HNSCC anatomical region includes tumours of the oral cavity, pharynx and larynx and the most common histological type is squamous cell carcinoma, present in 95% of cases \[[@R2], [@R3]\]. Alcohol and tobacco use are common factors for HNSCC. Additionally, evidence is accumulating for a role of folate in cancer. Studies have shown a relationship between polymorphisms of genes involved in folate metabolism and the HNSCC risk because of their influence on methylation and synthesis of DNA \[[@R2], [@R4]-[@R11]\].

Methylation is responsible for gene expression control, chromatin structure stability and the maintenance of genomic stability. Folate, the methyl donor in reaction to cellular methylation, regulates the synthesis, methylation and repair of DNA when present in the body in adequate amounts. When folate is altered in consequence of polymorphism in this pathway, it disrupts the cell cycle and consequently may lead to cancer \[[@R5], [@R12]-[@R14]\].

The *CBS* gene encodes cystathionine beta synthase (*CBS*), involved in the folate pathway, which is the central enzyme in the transsulfuration pathway that irreversibly metabolizes homocysteine (Hcy) (removes Hcy from the methionine) to cystathionine. It is polymorphic in nucleotide 844 -- exon 8 (*CBS* 844ins68) with an insertion of 68 base pairs. Although the biological impact of this polymorphism remains unclear, it seems to be associated with reduction of Hcy levels and changes in DNA methylation because of the low availability of S-adenosylmethionine (SAdoMet), the main methyl donor for methylation reactions, and consequently DNA hypomethylation and carcino­genesis may occur \[[@R15]-[@R17]\].

The study of Le Marchand *et al.* \[[@R18]\] showed that the *CBS* 844ins68 variant allele may be protective against colorectal cancer, but this association occurs together with other polymorphisms of the folate pathway. The study of Pufulete *et al.* \[[@R19]\] did not find an association with colorectal cancer. Other studies also did not confirm an association between the polymorphism and carcinomas of the upper gastrointestinal tract \[[@R20]\] and prostate cancer \[[@R21]\].

The association between head and neck squamous cell carcinoma and *CBS* 844ins68 polymorphism has not been tested until now; thus, we have conducted this case-control study in 853 in­di­viduals to investigate the association between *CBS* 844ins68 polymorphism and HNSCC aetiology. Therefore, this study aimed to investigate the frequency of *CBS* 844ins68 in head and neck squamous cell carcinoma patients, to compare the results with individuals without cancer, and to evaluate the association of the polymorphism with risk factors (tobacco and alcohol habits) and clinical histopathological parameters.

Material and methods
====================

Study subjects
--------------

At first, the study protocol was approved by the National Ethics Committee (CONEP -- 5566/2005; SISNEP 0976.0.140.000-05).

The retrospective study population included a total of eight hundred and fifty-three subjects (322 patients and 531 controls) with a mean age of 52.5 ±13.7 years. The case group (86.7% men and 13.3% women) was treated at the Hospital de Base, a Public Institution, São José do Rio Preto, São Paulo, Brazil. Diagnosis was made from pathological specimens after either total excision or biopsy. Patients with squamous cell carcinoma tumour cell types were included and patients previously treated for tumours were excluded.

The tumours were classified according to the TNM classification following three criteria: extension of the tumour (T), presence of regional lymph node involvement (N) and presence of metastasis at a distance (M) \[[@R22]\]. The clinical stage (TNM) was used to analyse aggressiveness, with tumours being grouped as non-aggressive (stage I and II) and aggressive (stage III and IV). All required information about clinical histopathological parameters was obtained from the patients' medical records.

The control group comprised Brazilian blood donors (72.3% men and 27.7% women) without cancer according to the government guidelines for blood donation which include tests for 20 related diseases (<http://www.hemonline.com.br/portarias/rdc153/indexframe.htm>). Individuals with family history of cancer were excluded and individuals aged over 40 years were included in this study. Each eligible subject was interviewed to obtain data on age, gender, smoking habits, use of alcohol and familial history of cancer.

The variables analysed were gender, exposure to risk factors (tobacco and alcohol consumption), and primary site of occurrence, aggressiveness, extension of the tumour and lymph node involvement. Individuals who had smoked more than 100 cigarettes during their lifetime were considered smokers. Individuals who drank four units of alcohol per week were considered alcohol consumers \[[@R23], [@R24]\].

Genotyping of *CBS* 844ins68
----------------------------

To determine the individual genotypes, genomic DNA was obtained from peripheral blood according to the technique of Miller *et al*. \[[@R25]\]. Molecular analysis of the *CBS* 844ins68 polymorphism was performed according to PCR technique (polymerase chain reaction) observing the difference in size of amplification products, using primer sequences described by Dutta *et al.* \[[@R26]\].

Amplification was obtained with initial denaturation at 94°C for 4 min, followed by 30 cycles of 1 minute of DNA denaturation at 94°C, 1 min of primer annealing at 62°C and 1 min of extension at 72°C. A final extension of 5 min at 72°C was carried out. The PCR products were run onto 1.5% agarose gel, stained with ethidium bromide and visualized in UV illumination. The *CBS* gene thus included (I) or lacked (N) a 68 base pairs (bp) insertion at exon 8. The major allele (I) presented a 239 bp fragment and the normal allele presented a 171 bp fragment. Fragment sizes were estimated by comparing with a 100 bp DNA size marker.

Statistical analysis
--------------------

Statistical analysis was performed using Minitab software (Windows, Version 14.0) and the BioEstat program. Chi-square tests were conducted to examine whether the genotype frequency of *CBS* 844ins68 was in Hardy-Weinberg equilibrium (HWE).

Differences in gender (reference: female), tobacco (reference: non-smokers) and alcohol habits (reference: non-drinkers) between the cases and controls were evaluated using multiple logistic regression analysis. This model was also used to determine the interaction effect between the genetic polymorphism and variables related to head and neck squamous cell carcinoma.

The clinical histopathological parameters were analysed by multiple logistic regression. Tumours were classified as low T (T1, T2) and high T (T3, T4). The N classification was dichotomized into no lymph node involvement (N0) and involvement (N1, N2, N3). Tumours were divided into early stage (stages I and II) and advanced stage (stages III and IV) categories. A *p* value \< 0.05 was considered statistically significant. Results are shown as odds ratio (OR) and 95% confidence intervals (95% CI).

The Kaplan-Meier method was used to evaluate survival rates and recurrence time of disease. The log-rank test was used to assess differences related to the different genotypes.

Results
=======

Demographic data and lifestyle factors
--------------------------------------

The case group with a mean age of 58.4 (9.9) years presented a predominance of tobacco (80.7%) and alcohol consumers (69.2%). The mean age of the control group was 47.4 (13.1) years, 40.4% tobacco users and 49.2% alcohol consumers.

As matching demographic data and risk factors between patients with cancer and control individuals was not possible, multivariable analysis was performed to adjust these variables. There were statistically significant differences between patients and controls according to age \> 50 years (OR 7.89, 95% CI: 5.56-11.21, *p* \< 0.05), male gender (OR 1.05, 95% CI: 1.05-2.67, *p* \< 0.05) and tobacco users (OR 4.09, 95% CI, 2.77-6.03, *p* \< 0.05).

*CBS* genotype
--------------

The Hardy-Weinberg equilibrium showed that the genotypic distributions were not expected in both groups and they were not in equilibrium (case: χ^2^ = 4.98, *p* = 0.02 and control: χ^2^ = 8.05, *p* = 0.004).

The genotypic and allelic distributions of the *CBS* 844ins68 polymorphism were compared between the groups and did not show statistically significant differences. Of 854 individuals studied, 702 (82.2%, 443 controls and 259 patients) comprising did not have the polymorphism; 18 (2.1%, 10 controls and 8 patients) presented *CBS* 844ins68 polymorphism, and 134 (15.7%, 78 controls and 56 patients) had the heterozygous genotype for the polymorphism (Table [I](#T1){ref-type="table"}).

The potential interaction between the distribution of the *CBS* 844ins68 genotype and exposure to risk factors for head and neck squamous cell carcinoma are shown in Table [II](#T2){ref-type="table"}, with no statistical difference.

Clinical histopathological parameters and *CBS*polymorphism
-----------------------------------------------------------

Only patients with complete pathological data were considered for this analysis. There were significant associations of individuals with IN and II genotypes (at least one 68p insertion allele) with oral cavity (OR 1.93, 95% CI: 1.10-3.40, *p* \< 0.05) (Table [III](#T3){ref-type="table"}). The analysis of metastasis classification was not performed since all patients were classified as M0.

The Kaplan-Meier survival curves by genotype are presented in Figure [1](#F1){ref-type="fig"}. There was an association between polymorphism and survival time (*p*= 0.02) (Figure [1A](#F1){ref-type="fig"}), and no association between polymorphism and recurrence time of the disease (Figure [1B](#F1){ref-type="fig"}, *p* = 0.52).

Discussion
==========

The results showed that HNSCC is more common in male smokers aged over 50 years. Previous studies have shown that male gender, alcohol and tobacco consumption are the most important predisposing factors for this disease \[[@R2], [@R27]-[@R29]\]. In our study, however, alcohol consumption was not associated with HNSCC. A multicentre study confirmed that tobacco is a strong risk factor for HNSCC independent of alcohol consumption \[[@R30]\]. Moreover, studies in animal models showed that alcohol did not have a direct carcinogenic effect and it is not genotoxic. This agent suppresses the removal of nitrosamine molecules of low molecular weight released by the tobacco in the liver through inhibition of multiple isoforms of the cytochrome P450 superfamily. Thus, there is an increase of nitrosamines to the post-hepatic tissues and an increase in the formation of DNA adducts \[[@R31]-[@R33]\].

Male gender remains the most affected by this tumour type as shown in our findings. However, the female gender has been presenting higher proportions \[[@R27], [@R29]\], due to the habits of the smoking and alcohol consumption have increased among women \[[@R2]\].

According to Hardy-Weinberg equilibrium (HWE) analysis, our study showed that the *CBS* gene is not in HWE. The departure from the HWE may result from the random selection of the studied individuals, the disease model adopted, and evolutionary factors which can influence changes in the genotype frequencies \[[@R34], [@R35]\]. On the other hand, this disequilibrium should be expected, considering that it reflects biological and genetic characteristics in complex disease models \[[@R36]\].

In our case-control study the *CBS* 68 bp insertion allele (I) was not statistically significantly associated with HNSCC risk (OR 1.20, 95% CI: 0.85-1.71, *p* = 0.30); nor with heterozygous genotype (I/N) or polymorphic homozygous genotype (I/I), with OR of 1.15 (95% CI: 0.74-1.79, *p* = 53). We did not find evidence that the *CBS* 844ins68 polymorphism may contribute to the individual risk for the development of head and neck squamous cell carcinoma, in as studies of Kimura *et al*. \[[@R21]\] and Ott *et al.* \[[@R20]\] in prostate and upper gastrointestinal tract cancer, respectively.

Ott *et al.* \[[@R20]\] investigated the insertion of 68 bp in the *CBS* gene with susceptibility to carcinomas of the upper gastrointestinal tract. They studied 263 patients with oesophageal cancer, 89 patients with Barrett's oesophagus-associated oesophageal adenocarcinoma, 144 with cardiac carcinoma, 221 with gastric cancer and 257 healthy subjects, and they did not find an association with these neoplasms. The study of Kimura *et al.* \[[@R21]\] in 132 patients with prostate cancer and 150 individuals without cancer, and the study of Pufullete *et al.* \[[@R19]\] that investigated 35 patients with adenoma, 28 patients with colorectal cancer and 76 controls did not found association with cancer risk.

The study of Le Marchand *et al.* \[[@R18]\] found an association of *CBS* 844ins68 and cancer risk. They investigated 727 Japanese, Caucasian, or Native Hawaiian colorectal cases and 727 controls without neoplasia matched for sex, age, and ethnicity and showed that *CBS* 844ins68 variant allele may be weakly protective against colorectal cancer, but this effect occurs only if this variant acts together with the T allele (variant) of *MTHFR* C677T polymorphism.

Our results for a potential interaction between the distribution of the *CBS* 844ins68 genotype and exposure to risk factors for head and neck squamous cell carcinoma did not show any statistically significant association. Kimura *et al.* \[[@R21]\] found that the insertion allele was slightly more prevalent among females in homozygous or heterozygous form in the control group, and the polymorphic allele was rarer in older patients, but these differences were not statistically significant.

This polymorphism resides in a key enzyme of the one-carbon metabolism pathway and it may result in aberrant DNA synthesis which may result in uncontrolled growth, but no study presented significant results for *CBS* 844ins68 polymorphism and cancer risk \[[@R15]-[@R17]\]. To our knowledge, this is the first study of *CBS* 844ins68 and HNSCC risk and despite the few studies in cancer, some studies have found an association of this polymorphism with other diseases, such as schizophrenia \[[@R37]\], neural tube defects \[[@R38]\], Alzheimer's disease \[[@R39]\] and coronary artery disease \[[@R40]\].

The *CBS* 844ins68 polymorphism was first reported in a homocystinuric patient by Sebastio *et al.* \[[@R41]\]. It was initially thought to mandate the use of an insertion-associated premature stop codon in the *CBS* mRNA leading to the translation of a truncated inactive enzyme. Subsequently Tsai *et al.* \[[@R15]\] showed that the 68 bp insertion generates an alternative splice site that permits the elimination of the entire inserted region, thereby allowing the formation of a normal mRNA transcript and a fully functional *CBS* enzyme. In 1998, De Stefano *et al.* \[[@R42]\] reported that *MTHFR* 677TT homozygous individuals carrying the *CBS* 844ins68 allele had lower homocysteine levels than non-carriers; however, folate levels were not presented in this report. More recently, Dekou *et al.* \[[@R43]\] also reported that the *CBS* 844ins68 allele appears to have a homocysteine-lowering effect in MTHFR 677TT homozygous individuals, but again no data were reported regarding the effect on folate levels.

In our study, it was not possible to measure the homocysteine and folate concentrations, but studies have reported that individuals who have the 68 bp insertion had increased homocysteine and folate levels compared with wild-type individuals \[[@R44], [@R45]\].

For clinical histopathological parameters analysed, our results suggest that the *CBS* --Insertion 68 bp allele was more frequent in patients with the oral cavity as the primary site. The tumour extent and lymph node involvement were not associated with the presence of the polymorphism. Kimura *et al.* \[[@R21]\] did not observe any association between the polymorphism and clinical parameters in prostate cancer.

The majority of HNSCC patients showed less advanced stage classified as T1/T2 and N0 (54.3% and 96%, respectively) in our study. Different of the literature data, which have shown a high frequency of head and neck squamous cell carcinoma in advanced stage (60% in stage III and IV) \[[@R46]\]. However, in gastric and cardiac cancer category tumour size T1 and T2 was more prevalent, as in our study in HNSCC \[[@R20]\].

No data were found in the literature assessing survival according to the *CBS* 844ins68 polymorphism in patients with HNSCC. According to Esher *et al.* \[[@R47]\], patients with HNSCC have a low survival rate among some cancer types. In spite of new surgical techniques, such as radiotherapy and concomitant chemotherapy, there has not been a significant increase in survival rate \[[@R48]-[@R50]\].

In conclusions, male gender and tobacco consumption are associated with HNSCC risk and there is no evidence of an association between *CBS* polymorphism and head and neck carcinogenesis risk. The polymorphism was associated with oral cavity primary site and with less survival time. Further studies in a larger population are required to better understand this polymorphism.
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###### 

Distribution of the CBS 844ins68 polymorphism between HNSCC patients and controls

  *CBS* 844ins68 polymorphism   Patients *n* (%)   Controls *n* (%)   OR (95% IC)        *P*
  ----------------------------- ------------------ ------------------ ------------------ ------
  **Genotypes**                 *n* = 322          *n* = 531                             
   NN (Non-insertion)           258 (80)           443 (83.4)         1.00 (ref)         
   IN (Heterozygous)            56 (17.5)          78 (14.6)          1.15 (0.74-1.79)   0.53
   II (Polymorphic)             08 (2.5)           10 (2.0)                              
  **Alleles**                                                                            
   Non insertion (N) 68bp       315 (83.1)         521 (82.8)         1.00 (ref)         
   Insertion 68 bp(I)           64 (16.9)          88 (17.2)          1.20 (0.85-1.71)   0.30

NN -- 68 bp non-insertion, IN -- heterozygous -- CBS 844ins68, II -- CBS 844ins68 polymorphic. Adjusted for age, gender, tobacco and alcohol habits. The genotypes was calculated for polymorphic homozygous individuals or carrying risk allele heterozygous vs. wild-type homozygous. p \< 0.05 was considered significant. There was no difference statistically significant (multiple logistic regression)

###### 

Odds Ratio of head and neck cancer related to CBS genotypes by age, gender, tobacco and alcohol habits

  Variables                         NN genotype (case/controls)   OR (95% CI)   IN and II genotype (cases/controls)   OR (95% CI)[\*](#T2F3){ref-type="table-fn"}   *P*
  --------------------------------- ----------------------------- ------------- ------------------------------------- --------------------------------------------- ------
  ** Age**                                                                                                                                                          
  \< 50                             53/313                        1.00 (ref)    10/60                                 1.19 (0.55-2.57)                              0.66
  \> 50                             205/130                       1.00 (ref)    54/28                                 1.18 (0.68-2.03)                              0.55
  ** Gender**                                                                                                                                                       
  Fitalicale                        34/125                        1.00 (ref)    08/22                                 1.34 (0.49-3.65)                              0.56
  Male                              224/318                       1.00 (ref)    56/66                                 1.12 (0.68- 1.83)                             0.65
  ** Tobacco habits**                                                                                                                                               
  No                                47/261                        1.00 (ref)    12/55                                 1.14 (0.52-2.50                               0.73
  Yes                               211/182                       1.00 (ref)    52/33                                 1.14 (0.66-1.95                               0.64
  ** Alcohol habits**                                                                                                                                               
  No                                81/221                        1.00 (ref)    18/48                                 1.10 (0.55-2.19)                              0.78
  Yes                               177/222                                     46/40                                 1.21 (0.67-2.17)                              0.53
  ** Tobacco and alcohol habits**                                                                                                                                   
  No                                38/151                        1.00 (ref)    08/36                                 0.79 (0.31-1.98)                              0.61
  Yes                               168/112                                     42/21                                 1.04 (0.56-1.93)                              0.90

CBS cystathionine β-synthase: NN -- 68 bp non-insertion, IN -- heterozygous -- CBS 844ins68, II -- CBS 844ins68 polymorphic genotype

Ajusted for age, gender, tobacco and alcohol habits. CBS IN and II genotype compared with variables -- reference: CBS NN; p \< 0.05 was considered significant. None of the differences between groups were statistically significant by multiple logistic regression.

###### 

Distribution of the clinical histopathological parameters and CBS polymorphism\*

  Variables               NN genotype   OR(95% CI)   IN/IIgenotype   OR (95% CI)\*\*    *P*
  ----------------------- ------------- ------------ --------------- ------------------ ---------
   Oral cavity            97            1.00 (ref)   33              1.93 (1.10-3.40)   \< 0.05
   Pharynx                65            1.00 (ref)   15              0.92 (0.48-1.76)   0.92
   Larynx                 85            1.00 (ref)   12              0.83 (0.50-1.36)   0.45
   Unknown primary site   11            1.00 (ref)   05              1.50 (0.46-4.88)   0.50
  **Tumor extension**                                                                   
   T1/T2                  106           1.00 (ref)   28              1.00 (ref)         
   T3/T4                  118           1.00 (ref)   29              0.48 (0.27-0.86)   0.63
  **N involvement**                                                                     
   No                     11            1.00 (ref)   01              1.00 (ref)         
   Yes                    213           1.00 (ref)   56              1.47 (0.37-5.75)   0.58

*CBS cystathionine β-synthase: NN -- 68 bp non-insertion, IN -- heterozygous -- CBS 844ins68, II -- CBS 844ins68 polymorphic genotype \*The analysis was made to patients with complete data. CBS IN and II genotype compared with clinical histopathological parameters -- reference:CBS NN; p \< 0.05 was considered significant. There was difference statistically significant between oral cavity and CBS polymorphism (multiple logistic regression)*
